Nuzenio

Tradingview Arct

Tradingview Arct entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 14 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Enterprise value to EBITDA forward of Arco Towers REIT – BSESOF:ARCT - TradingViewTradingView · Sun, 09 Aug 2026 22:18:44 GMTARCT: Advanced rare disease pipeline and regained global vaccine rights, with strong cash runway through 2028 - TradingViewTradingView · Thu, 06 Aug 2026 22:19:18 GMTArcturus Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 22:04:08 GMTArcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:35:07 GMTARCT: Q2 2026 revenue fell 90% as vaccine deal ended; focus shifts to pipeline and new Thermo Fisher partnership - TradingViewTradingView · Thu, 06 Aug 2026 20:26:25 GMTArcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingViewTradingView · Thu, 06 Aug 2026 20:13:22 GMTARCT: Advanced rare disease pipeline, regained key vaccine rights, and secured cash runway through 2028 - TradingViewTradingView · Thu, 06 Aug 2026 20:08:15 GMTBRIEF-Arcturus Therapeutics Q2 Net Income USD -23.785 Million - TradingViewTradingView · Thu, 06 Aug 2026 20:02:01 GMT

Timeline

Sun, 09 Aug 2026 22:18:44 GMTEnterprise value to EBITDA forward of Arco Towers REIT – BSESOF:ARCT - TradingView
Thu, 06 Aug 2026 22:19:18 GMTARCT: Advanced rare disease pipeline and regained global vaccine rights, with strong cash runway through 2028 - TradingView
Thu, 06 Aug 2026 22:04:08 GMTArcturus Therapeutics Q2 Earnings Call Highlights - TradingView
Thu, 06 Aug 2026 20:35:07 GMTArcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingView
Thu, 06 Aug 2026 20:26:25 GMTARCT: Q2 2026 revenue fell 90% as vaccine deal ended; focus shifts to pipeline and new Thermo Fisher partnership - TradingView
Thu, 06 Aug 2026 20:13:22 GMTArcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Arct.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.